ESMO TAT 2027 takes place in Paris from 22–24 February and focuses on early-phase clinical development and translational research in targeted anticancer therapies. It brings together academic researchers, clinicians and industry teams to discuss emerging agents, novel combinations and biomarker-driven development. The published overview highlights first-in-human development, mechanism of action, trial design, biomarker selection, resistance, toxicity and how new agents fit into treatment pathways. This is particularly relevant to oncology trainees and academic clinicians involved in early-phase trials or precision medicine. The programme page is available, but abstract dates, fees, CPD points and detailed presentation formats were not yet published in the inspected content. The source confirms an international scientific meeting rather than a course, with a strong emphasis on hypothesis-generating data, clinical research partnerships and early drug development. The venue is Paris, with accommodation and venue pages linked for later enrichment.